Vicki Sato Reports Vir Biotechnology Security Changes

TL;DR

Vicki Sato updated her Vir Bio holdings on 4/1/26.

AI Summary

On April 1, 2026, Vicki L. Sato reported a change in beneficial ownership of securities for Vir Biotechnology, Inc. The filing, dated April 2, 2026, details transactions related to her holdings in the company.

Why It Matters

This filing provides insight into the trading activity and beneficial ownership changes of a key executive at Vir Biotechnology, Inc.

Risk Assessment

Risk Level: low — Form 4 filings typically report routine changes in beneficial ownership by insiders and do not inherently signal significant risk.

Key Numbers

• 2026-04-01 — Period of Report (Date of reported transactions)
• 2026-04-02 — Filing Date (Date the report was officially submitted)

Key Players & Entities

• Vicki L. Sato (person) — Reporting Person
• Vir Biotechnology, Inc. (company) — Issuer
• 0001706431 (company) — Vir Biotechnology CIK
• 0001197020 (person) — Vicki L. Sato CIK

FAQ

Key Financial Figures

• $8.87 — ple transactions at prices ranging from $8.87 to $9.20, inclusive. The Reporting Pers
• $9 — actions at prices ranging from $8.87 to $9.20, inclusive. The Reporting Person und

Filing Documents

• wk-form4_1775141198.html (4)
• wk-form4_1775141198.xml (4) — 4KB
• 0001628280-26-022971.txt ( ) — 5KB

From the Filing

SEC FORM 4 SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). X Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. 1. Name and Address of Reporting Person * SATO VICKI L (Last) (First) (Middle) C/O VIR BIOTECHNOLOGY, INC. 1800 OWENS STREET, SUITE 900 (Street) SAN FRANCISCO CALIFORNIA 94158 (City) (State) (Zip) UNITED STATES (Country) 2. Issuer Name and Ticker or Trading Symbol Vir Biotechnology, Inc. [ VIR ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title below) Other (specify below) 2a. Foreign Trading Symbol 3. Date of Earliest Transaction (Month/Day/Year) 04/01/2026 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person 4. If Amendment, Date of Original Filed (Month/Day/Year) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 04/01/2026 S (1) 22,000 D $ 9.0735 (2) 1,100,391 D Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Explanation of Responses: 1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2025. 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.87 to $9.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Remarks: /s/ Vanina de Verneuil, Attorney-In-Fact 04/02/2026 ** Signature of Reporting Person Date Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. * Form 4: SEC 1474 (03-26)

View Full Filing

View this 4 filing on SEC EDGAR